Skip to main content
. Author manuscript; available in PMC: 2024 Apr 2.
Published in final edited form as: Mol Cancer Ther. 2023 Oct 2;22(10):1166–1181. doi: 10.1158/1535-7163.MCT-23-0196

Figure 3. MPC309 promotes a unique transcriptome.

Figure 3.

LNCaP-abl cells were cultured under androgen deprivation and treated with vehicle (DMSO), 1μM backbone, 1μM MPC309, 10nM DHT, or 10μM enzalutamide overnight, and RNA-seq performed. (A) Venn diagrams show the number of unique and common genes upregulated and downregulated by MPC309 (vs. vehicle and backbone controls) and by DHT or enzalutamide treatments (vs. vehicle control) (1.25-fold, p <0.05). (B) Heatmap of differentially expressed genes in MPC309-treated vs. DHT-treated cells. Pathway analysis was performed using the Molecular Signatures Database (MSigDB). (C) Pathways associated with specific genes downregulated by MPC309 vs. DHT.